Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease.

Introduction Hydroxyurea (HU) improves hematologic parameters and decreases adverse events in patients with sickle cell disease (SCD). HU has been proposed as an alternative to chronic transfusions for secondary stroke prevention. Transcranial doppler (TCD) is an accepted method of stroke risk stratification in patients with SCD. We sought to determine if HU affects TCD velocities in children with SCD. Methods A cohort of 24 children with HbSS with a baseline TCDi prior to HU and a follow-up after at least 6 months of therapy was analyzed. Twenty-four age-matched children with HbSS formed the control group. Differences in hematologic parameters before and after HU therapy were evaluated. Results TCDi velocities decreased in the HU-treated patients. The adjusted mean change in TCDi velocities was −13.0 cm/sec (95% CI −20.19, −5.92) in the HU-treated group and +4.72 cm/sec (95% CI −3.24, 12.69) in the controls. Changes in TCDi between the two groups were statistically significant (P  170 cm/sec had normalization of TCDi velocities on HU. Mean change was −34.75 cm/sec in this subgroup. No patients experienced cerebrovascular accidents (CVA) while on HU. Conclusions HU-treated patients experienced statistically significant decreases in TCDi velocities compared to age-matched controls. Changes in hematologic parameters were not predictive of changes in TCDi velocities in the treated group. The decrease in TCDi velocities is not a consequence of changes in hematologic values in patients treated with HU. Pediatr Blood Cancer © 2006 Wiley-Liss, Inc.